Show simple item record

dc.contributor.authorAKTUGLU, G
dc.contributor.authorULUTIN, O
dc.contributor.authorZISSIS, NP
dc.contributor.authorULKU, B
dc.date.accessioned2021-03-03T21:20:56Z
dc.date.available2021-03-03T21:20:56Z
dc.date.issued1994
dc.identifier.citationULKU B., AKTUGLU G., ZISSIS N., ULUTIN O., "MITOXANTRONE AND CYTOSINE-ARABINOSIDE AS 1ST-LINE INDUCTION THERAPY IN NEWLY-DIAGNOSED ACUTE NONLYMPHOCYTIC LEUKEMIA", CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, cilt.55, sa.5, ss.552-558, 1994
dc.identifier.issn0011-393X
dc.identifier.otherav_5ebd01a4-128a-41ea-a277-819b57ffaeef
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/66216
dc.identifier.urihttps://doi.org/10.1016/s0011-393x(05)80186-9
dc.description.abstractThirty-three patients (22 men and 11 women; median age, 44 years) with newly diagnosed acute nonlymphocytic leukemia (ANLL) were treated with a combination of mitoxantrone, an anthracenedione derivative, 10 mg/m2/d for 3 days, plus cytosine arabinoside (ara-c), 100 mg/m2/d for 7 days. Patients not responding after two courses of therapy were considered treatment failures. Responding patients received two consolidation courses. Complete remission was achieved in 24 patients (73%) half of whom responded after a single course of therapy. Two patients were refractory and 7 died due to bone marrow depression. The median disease-free survival was 390 days, and the median overall survival was 450 days; 2 patients were still alive after 979 and 1166 days, respectively. Apart from hematologic findings, the most commonly observed toxicities were nausea/vomiting, alopecia, and infection. Mitoxantrone combined with ara-c is an effective and safe combination in the treatment of newly diagnosed ANLL.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.titleMITOXANTRONE AND CYTOSINE-ARABINOSIDE AS 1ST-LINE INDUCTION THERAPY IN NEWLY-DIAGNOSED ACUTE NONLYMPHOCYTIC LEUKEMIA
dc.typeMakale
dc.relation.journalCURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
dc.contributor.department, ,
dc.identifier.volume55
dc.identifier.issue5
dc.identifier.startpage552
dc.identifier.endpage558
dc.contributor.firstauthorID115238


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record